Koch M, Mostert J, Arutjunyan A V, Stepanov M, Teelken A, Heersema D, De Keyser J
Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Eur J Neurol. 2007 May;14(5):529-33. doi: 10.1111/j.1468-1331.2007.01739.x.
Oxidative stress has been implicated in the pathophysiology of multiple sclerosis (MS), but its relation to disease progression is uncertain. To evaluate the relationship of plasma lipid peroxidation with progression of disability in MS, we measured blood plasma fluorescent lipid peroxidation products (PFLPP) levels in 23 patients with RRMS with a benign course, 32 with secondary progressive MS, 24 with primary progressive MS and 30 healthy controls. None of the patients had a relapse within the previous 3 months. Progression of disability was evaluated during a follow-up period of 5 years by the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSSS). We found plasma PFLPP levels elevated in patients with MS compared with controls (P < 0.0001), but there was no difference between patients with a benign and progressive disease course. There was no correlation between PFLPP levels and worsening of disability on the EDSS and speed of progression on the MSSS. Our data suggest that there is no relation between the degree of oxidative stress in plasma and progression of disability in MS.
氧化应激与多发性硬化症(MS)的病理生理学有关,但其与疾病进展的关系尚不确定。为了评估血浆脂质过氧化与MS患者残疾进展之间的关系,我们测量了23例病情良性的复发缓解型MS患者、32例继发进展型MS患者、24例原发进展型MS患者以及30名健康对照者的血浆荧光脂质过氧化产物(PFLPP)水平。所有患者在过去3个月内均未复发。在5年的随访期内,通过扩展残疾状态量表(EDSS)和多发性硬化症严重程度评分(MSSS)评估残疾进展情况。我们发现,与对照组相比,MS患者的血浆PFLPP水平升高(P < 0.0001),但病情良性和进展型患者之间没有差异。PFLPP水平与EDSS上残疾程度的恶化以及MSSS上的进展速度之间没有相关性。我们的数据表明,血浆氧化应激程度与MS患者的残疾进展之间没有关系。